Roles of matrix metalloproteinases and their natural inhibitors in prostate cancer progression

Cancers

Volumn 6, Issue 3, 2014, Pages 1298-1327

  Gong, Yixuan ^a   Chippada Venkata, Uma D ^a   Oh, William K ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

MMP; Prostate cancer; TIMP

Indexed keywords

BATIMASTAT; BB 094; GELATINASE A; GELATINASE B; MARIMASTAT; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 15; MATRIX METALLOPROTEINASE 26; MATRIX METALLOPROTEINASE INHIBITOR; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CARCINOGENESIS; CELL MIGRATION; DRUG DOSE COMPARISON; DRUG RESPONSE; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; ENZYME STRUCTURE; EXTRACELLULAR MATRIX; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MUSCULOSKELETAL DISEASE; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; TUMOR INVASION; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

EID: 84903517149     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers6031298     Document Type: Review

References (164)

1. Siegel, R.; Ma, J.; Zou, Z.; Jemal, A. Cancer statistics, 2014. CA Cancer J. Clin. 2014, 64, 9-29.
2. Bellmunt, J.; Oh, W. K. Castration-resistant prostate cancer: New science and therapeutic prospects. Ther. Adv. Med. Oncol. 2010, 2, 189-207.
3. De Bono, J. S.; Oudard, S.; Ozguroglu, M.; Hansen, S.; Machiels, J. P.; Kocak, I.; Gravis, G.; Bodrogi, I.; Mackenzie, M. J.; Shen, L.; et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 2010, 376, 1147-1154.
4. Kantoff, P. W.; Higano, C. S.; Shore, N. D.; Berger, E. R.; Small, E. J.; Penson, D. F.; Redfern, C. H.; Ferrari, A. C.; Dreicer, R.; Sims, R. B.; et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 2010, 363, 411-422.
5. Parker, C.; Nilsson, S.; Heinrich, D.; Helle, S. I.; O'Sullivan, J. M.; Fossa, S. D.; Chodacki, A.; Wiechno, P.; Logue, J.; Seke, M.; et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N. Engl. J. Med. 2013, 369, 213-223.
6. Vapiwala, N.; Glatstein, E. Radium-223 in prostate cancer. N. Engl. J. Med. 2013, 369, 1660.
7. Liotta, L. A.; Kohn, E. C. The microenvironment of the tumour-host interface. Nature 2001, 411, 375-379.
8. Coussens, L. M.; Werb, Z. Inflammation and cancer. Nature 2002, 420, 860-867.
9. Overall, C. M.; Lopez-Otin, C. Strategies for MMP inhibition in cancer: Innovations for the post-trial era. Nat. Rev. Cancer 2002, 2, 657-672.
10. Stocker, W.; Grams, F.; Baumann, U.; Reinemer, P.; Gomis-Ruth, F. X.; McKay, D. B.; Bode, W. The metzincins-topological and sequential relations between the astacins, adamalysins, serralysins, and matrixins (collagenases) define a superfamily of zinc-peptidases. Protein Sci. 1995, 4, 823-840.
11. Hanahan, D.; Weinberg, R. A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646-674.
12. Kessenbrock, K.; Plaks, V.; Werb, Z. Matrix metalloproteinases: Regulators of the tumor microenvironment. Cell 2010, 141, 52-67.
13. Gialeli, C.; Theocharis, A. D.; Karamanos, N. K. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J. 2011, 278, 16-27.
14. Coussens, L. M.; Fingleton, B.; Matrisian, L. M. Matrix metalloproteinase inhibitors and cancer: Trials and tribulations. Science 2002, 295, 2387-2392.
15. Sternlicht, M. D.; Werb, Z. How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell Dev. Biol. 2001, 17, 463-516.
16. Yan, C.; Boyd, D. D. Regulation of matrix metalloproteinase gene expression. J. Cell Physiol. 2007, 211, 19-26.
17. Overall, C. M.; Wrana, J. L.; Sodek, J. Transcriptional and post-transcriptional regulation of 72-kDa gelatinase/type IV collagenase by transforming growth factor-beta 1 in human fibroblasts. Comparisons with collagenase and tissue inhibitor of matrix metalloproteinase gene expression. J. Biol. Chem. 1991, 266, 14064-14071.
18. Harper, E.; Bloch, K. J.; Gross, J. The zymogen of tadpole collagenase. Biochemistry 1971, 10, 3035-3041.
19. Hadler-Olsen, E.; Grams, F.; Baumann, U.; Reinemer, P.; Gomis-Ruth, F. X.; McKay, D. B.; Bode, W. Regulation of matrix metalloproteinase activity in health and disease. FEBS J. 2011, 278, 28-45.
20. Murphy, G. Tissue inhibitors of metalloproteinases. Genome Biol. 2011, 12, 233.
21. Nagase, H.; Visse, R.; Murphy, G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc. Res. 2006, 69, 562-573.
22. Curran, S.; Murray, G. I. Matrix metalloproteinases: Molecular aspects of their roles in tumour invasion and metastasis. Eur. J. Cancer 2000, 36, 1621-1630.
23. Brew, K.; Nagase, H. The tissue inhibitors of metalloproteinases (TIMPs): An ancient family with structural and functional diversity. Biochim. Biophys. Acta 2010, 1803, 55-71.
24. Moore, C. S.; Crocker, S. J. An alternate perspective on the roles of TIMPs and MMPs in pathology. Am. J. Pathol. 2012, 180, 12-16.
25. Littlepage, L. E.; Sternlicht, M. D.; Rougier, N.; Phillips, J.; Gallo, E.; Yu, Y.; Williams, K.; Brenot, A.; Gordon, J. I.; Werb, Z. Matrix metalloproteinases contribute distinct roles in neuroendocrine prostate carcinogenesis, metastasis, and angiogenesis progression. Cancer Res. 2010, 70, 2224-2234.
26. Jung, K.; Nowak, L.; Lein, M.; Priem, F.; Schnorr, D.; Loening, S. A. Matrix metalloproteinases 1 and 3, tissue inhibitor of metalloproteinase-1 and the complex of metalloproteinase-1/tissue inhibitor in plasma of patients with prostate cancer. Int. J. Cancer 1997, 74, 220-223.
27. Ozden, F.; Saygin, C.; Uzunaslan, D.; Onal, B.; Durak, H.; Aki, H. Expression of MMP-1, MMP-9 and TIMP-2 in prostate carcinoma and their influence on prognosis and survival. J. Cancer Res. Clin. Oncol. 2013, 139, 1373-1382.
28. Still, K.; Robson, C. N.; Autzen, P.; Robinson, M. C.; Hamdy, F. C. Localization and quantification of mRNA for matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of matrix metalloproteinase-2 (TIMP-2) in human benign and malignant prostatic tissue. Prostate 2000, 42, 18-25.
29. Wood, M.; Fudge, K.; Mohler, J. L.; Frost, A. R.; Garcia, F.; Wang, M.; Stearns, M. E. In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer. Clin. Exp. Metastasis 1997, 15, 246-258.
30. Stearns, M. E.; Wang, M. Type IV Collagenase (Mr 72, 000) expression in human prostate: Benign and malignant tissue. Cancer Res. 1993, 53, 878-883.
31. Gohji, K.; Fujimoto, N.; Hara, I.; Fujii, A.; Gotoh, A.; Okada, H.; Arakawa, S.; Kitazawa, S.; Miyake, H.; Kamidono, S. Serum matrix metalloproteinase-2 and its density in men with prostate cancer as a new predictor of disease extension. Int. J. Cancer 1998, 79, 96-101.
32. Stearns, M. E.; Stearns, M. Immunohistochemical studies of activated matrix metalloproteinase-2 (MMP-2a)expression in human prostate cancer. Oncol. Res. 1996, 8, 63-67.
33. Stearns, M.; Stearns, M. E. Evidence for increased activated metalloproteinase 2 (MMP-2a) expression associated with human prostate cancer progression. Oncol. Res. 1996, 8, 69-75.
34. Hashimoto, K.; Kihira, Y.; Matuo, Y.; Usui, T. Expression of matrix metalloproteinase-7 and tissue inhibitor of metalloproteinase-1 in human prostate. J. Urol. 1998, 160, 1872-1876.
35. Hamdy, F. C.; Fadlon, E. J.; Cottam, D.; Lawry, J.; Thurrell, W.; Silcocks, P. B.; Anderson, J. B.; Williams, J. L.; Rees, R. C. Matrix metalloproteinase 9 expression in primary human prostatic adenocarcinoma and benign prostatic hyperplasia. Br. J. Cancer 1994, 69, 177-182.
36. Morgia, G.; Falsaperla, M.; Malaponte, G.; Madonia, M.; Indelicato, M.; Travali, S.; Mazzarino, M. C. Matrix metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers of prostate cancer. Urol. Res. 2005, 33, 44-50.
37. Upadhyay, J.; Shekarriz, B.; Nemeth, J. A.; Dong, Z.; Cummings, G. D.; Fridman, R.; Sakr, W.; Grignon, D. J.; Cher, M. L. Membrane type 1-matrix metalloproteinase (MT1-MMP) and MMP-2 immunolocalization in human prostate: Change in cellular localization associated with high-grade prostatic intraepithelial neoplasia. Clin. Cancer Res. 1999, 5, 4105-4110.
38. Riddick, A. C.; Shukla, C. J.; Pennington, C. J.; Bass, R.; Nuttall, R. K.; Hogan, A.; Sethia, K. K.; Ellis, V.; Collins, A. T.; Maitland, N. J.; et al. Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues. Br. J. Cancer 2005, 92, 2171-2180.
39. Boag, A. H.; Young, I. D. Increased expression of the 72-kd type IV collagenase in prostatic adenocarcinoma. Demonstration by immunohistochemistry and in situ hybridization. Am. J. Pathol. 1994, 144, 585-591.
40. Kuniyasu, H.; Troncoso, P.; Johnston, D.; Bucana, C. D.; Tahara, E.; Fidler, I. J.; Pettaway, C. A. Relative expression of type IV collagenase, E-cadherin, and vascular endothelial growth factor/vascular permeability factor in prostatectomy specimens distinguishes organ-confined from pathologically advanced prostate cancers. Clin. Cancer Res. 2000, 6, 2295-2308.
41. Ross, J. S.; Kaur, P.; Sheehan, C. E.; Fisher, H. A.; Kaufman, R. A., Jr.; Kallakury, B. V. Prognostic significance of matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expression in prostate cancer. Mod. Pathol. 2003, 16, 198-205.
42. Brehmer, B.; Biesterfeld, S.; Jakse, G. Expression of matrix metalloproteinases (MMP-2 and-9) and their inhibitors (TIMP-1 and-2) in prostate cancer tissue. Prostate Cancer Prostat. Dis. 2003, 6, 217-222.
43. Cardillo, M. R.; di Silverio, F.; Gentile, V. Quantitative immunohistochemical and in situ hybridization analysis of metalloproteinases in prostate cancer. Anticancer Res. 2006, 26, 973-982.
44. Murray, N. P.; Reyes, E.; Tapia, P.; Badínez, L.; Orellana, N. Differential expression of matrix metalloproteinase-2 expression in disseminated tumor cells and micrometastasis in bone marrow of patients with nonmetastatic and metastatic prostate cancer: Theoretical considerations and clinical implications-An immunocytochemical study. Bone Marrow Res. 2012, 2012, 9.
45. Bodey, B.; Bodey, B., Jr.; Siegel, S. E.; Kaiser, H. E. Immunocytochemical detection of matrix metalloproteinase expression in prostate cancer. In Vivo 2001, 15, 65-70.
46. Trudel, D.; Fradet, Y.; Meyer, F.; Têtu, B. Matrix metalloproteinase 9 is associated with Gleason score in prostate cancer but not with prognosis. Hum. Pathol. 2010, 41, 1694-1701.
47. Knox, J. D.; Wolf, C.; McDaniel, K.; Clark, V.; Loriot, M.; Bowden, G. T.; Nagle, R. B. Matrilysin expression in human prostate carcinoma. Mol. Carcinog. 1996, 15, 57-63.
48. Szarvas, T.; Becker, M.; Vom Dorp, F.; Meschede, J.; Scherag, A.; Bankfalvi, A.; Reis, H.; Schmid, K. W.; Romics, I.; Rubben, H.; et al. Elevated serum matrix metalloproteinase 7 levels predict poor prognosis after radical prostatectomy. Int. J. Cancer 2011, 128, 1486-1492.
49. Oh, W. K.; Vargas, R.; Jacobus, S.; Leitzel, K.; Regan, M. M.; Hamer, P.; Pierce, K.; Brown-Shimer, S.; Carney, W.; Ali, S. M.; et al. Elevated plasma tissue inhibitor of metalloproteinase-1 levels predict decreased survival in castration-resistant prostate cancer patients. Cancer 2011, 117, 517-525.
50. Trudel, D.; Fradet, Y.; Meyer, F.; Harel, F.; Têtu, B. Significance of MMP-2 expression in prostate cancer: An immunohistochemical study. Cancer Res. 2003, 63, 8511-8515.
51. Boxler, S.; Djonov, V.; Kessler, T. M.; Hlushchuk, R.; Bachmann, L. M.; Held, U.; Markwalder, R.; Thalmann, G. N. Matrix metalloproteinases and angiogenic factors: Predictors of survival after radical prostatectomy for clinically organ-confined prostate cancer? Am. J. Pathol. 2010, 177, 2216-2224.
52. Reis, S. T.; Pontes-Junior, J.; Antunes, A. A.; de Sousa-Canavez, J. M.; Dall'Oglio, M. F.; Passerotti, C. C.; Abe, D. K.; Crippa, A.; da Cruz, J. A.; Timoszczuk, L. M.; et al. MMP-9 overexpression due to TIMP-1 and RECK underexpression is associated with prognosis in prostate cancer. Int. J. Biol. Mark. 2011, 26, 255-261.
53. Incorvaia, L.; Badalamenti, G.; Rini, G.; Arcara, C.; Fricano, S.; Sferrazza, C.; Di Trapani, D.; Gebbia, N.; Leto, G. MMP-2, MMP-9 and activin A blood levels in patients with breast cancer or prostate cancer metastatic to the bone. Anticancer Res. 2007, 27, 1519-1525.
54. Roy, R.; Louis, G.; Loughlin, K. R.; Wiederschain, D.; Kilroy, S. M.; Lamb, C. C.; Zurakowski, D.; Moses, M. A. Tumor-specific urinary matrix metalloproteinase fingerprinting: Identification of high molecular weight urinary matrix metalloproteinase species. Clin. Cancer Res. 2008, 14, 6610-6617.
55. Miyake, H.; Muramaki, M.; Kurahashi, T.; Takenaka, A.; Fujisawa, M. Expression of potential molecular markers in prostate cancer: Correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. Urol. Oncol. 2010, 28, 145-151.
56. Pajouh, M. S.; Nagle, R. B.; Breathnach, R.; Finch, J. S.; Brawer, M. K.; Bowden, G. T. Expression of metalloproteinase genes in human prostate cancer. J. Cancer Res. Clin. Oncol. 1991, 117, 144-150.
57. Chambers, A. F.; Matrisian, L. M. Changing views of the role of matrix metalloproteinases in metastasis. J. Natl. Cancer Instit. 1997, 89, 1260-1270.
58. Fridman, R.; Toth, M.; Peña, D.; Mobashery, S. Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2). Cancer Res. 1995, 55, 2548-2555.
59. Levi, E.; Fridman, R.; Miao, H. Q.; Ma, Y. S.; Yayon, A.; Vlodavsky, I. Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1. Proc. Natl. Acad. Sci. USA 1996, 93, 7069-7074.
60. Lokeshwar, B. L.; Selzer, M. G.; Block, N. L.; Gunja-Smith, Z. Secretion of matrix metalloproteinases and their inhibitors (tissue inhibitor of metalloproteinases) by human prostate in explant cultures: Reduced tissue inhibitor of metalloproteinase secretion by malignant tissues. Cancer Res. 1993, 53, 4493-4498.
61. Bergers, G.; Brekken, R.; McMahon, G.; Vu, T. H.; Itoh, T.; Tamaki, K.; Tanzawa, K.; Thorpe, P.; Itohara, S.; Werb, Z.; et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2000, 2, 737-744.
62. Moroz, A.; Delella, F. K.; Lacorte, L. M.; Deffune, E.; Felisbino, S. L. Fibronectin induces MMP2 expression in human prostate cancer cells. Biochem. Biophys. Res. Commun. 2013, 430, 1319-1321.
63. Fang, J.; Shing, Y.; Wiederschain, D.; Yan, L.; Butterfield, C.; Jackson, G.; Harper, J.; Tamvakopoulos, G.; Moses, M. A. Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc. Natl. Acad. Sci. USA 2000, 97, 3884-3889.
64. Itoh, T.; Tanioka, M.; Yoshida, H.; Yoshioka, T.; Nishimoto, H.; Itohara, S. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res. 1998, 58, 1048-1051.
65. Westermarck, J.; Kahari, V. M. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J. 1999, 13, 781-792.
66. Yee, D.; Tang, Y.; Li, X.; Liu, Z.; Guo, Y.; Ghaffar, S.; McQueen, P.; Atreya, D.; Xie, J.; Simoneau, A.; et al. The Wnt inhibitory factor 1 restoration in prostate cancer cells was associated with reduced tumor growth, decreased capacity of cell migration and invasion and a reversal of epithelial to mesenchymal transition. Mol. Cancer 2010, 9, 162.
67. Lovaas, J. D.; Zhu, L.; Chiao, C. Y.; Byles, V.; Faller, D. V.; Dai, Y. SIRT1 enhances matrix metalloproteinase-2 expression and tumor cell invasion in prostate cancer cells. Prostate 2013, 73, 522-530.
68. Deryugina, E. I.; Ratnikov, B.; Monosov, E.; Postnova, T. I.; DiScipio, R.; Smith, J. W.; Strongin, A. Y. MT1-MMP initiates activation of pro-MMP-2 and integrin alphavbeta3 promotes maturation of MMP-2 in breast carcinoma cells. Exp. Cell Res. 2001, 263, 209-223.
69. Nishida, Y.; Miyamori, H.; Thompson, E. W.; Takino, T.; Endo, Y.; Sato, H. Activation of matrix metalloproteinase-2 (MMP-2) by membrane type 1 matrix metalloproteinase through an artificial receptor for ProMMP-2 generates active MMP-2. Cancer Res. 2008, 68, 9096-9104.
70. Wilson, S. R.; Gallagher, S.; Warpeha, K.; Hawthorne, S. J. Amplification of MMP-2 and MMP-9 production by prostate cancer cell lines via activation of protease-activated receptors. Prostate 2004, 60, 168-174.
71. Wilson, M. J.; Sellers, R. G.; Wiehr, C.; Melamud, O.; Pei, D.; Peehl, D. M. Expression of matrix metalloproteinase-2 and-9 and their inhibitors, tissue inhibitor of metalloproteinase-1 and-2, in primary cultures of human prostatic stromal and epithelial cells. J. Cell. Physiol. 2002, 191, 208-216.
72. Long, L.; Navab, R.; Brodt, P. Regulation of the Mr 72, 000 type IV collagenase by the type I insulin-like growth factor receptor. Cancer Res. 1998, 58, 3243-3247.
73. Stearns, M. E.; Wang, M.; Stearns, M. IL-10 blocks collagen IV invasion by "invasion stimulating factor" activated PC-3 ML cells: Upregulation of TIMP-1 expression. Oncol. Res. 1995, 7, 157-163.
74. Xiao, L. J.; Lin, P.; Lin, F.; Liu, X.; Qin, W.; Zou, H. F.; Guo, L.; Liu, W.; Wang, S. J.; Yu, X. G. ADAM17 targets MMP-2 and MMP-9 via EGFR-MEK-ERK pathway activation to promote prostate cancer cell invasion. Int. J. Oncol. 2012, 40, 1714-1724.
75. Liao, X.; Thrasher, J. B.; Pelling, J.; Holzbeierlein, J.; Sang, Q.-X. A.; Li, B. Androgen stimulates matrix metalloproteinase-2 expression in human prostate cancer. Endocrinology 2003, 144, 1656-1663.
76. Li, B. Y.; Liao, X. B.; Fujito, A.; Thrasher, J. B.; Shen, F. Y.; Xu, P. Y. Dual androgen-response elements mediate androgen regulation of MMP-2 expression in prostate cancer cells. Asian J. Androl. 2007, 9, 41-50.
77. Bruni-Cardoso, A.; Johnson, L. C.; Vessella, R. L.; Peterson, T. E.; Lynch, C. C. Osteoclast-derived matrix metalloproteinase-9 directly affects angiogenesis in the prostate tumor-bone microenvironment. Mol. Cancer Res. 2010, 8, 459-470.
78. Huang, X.; Chen, S.; Xu, L.; Liu, Y.; Deb, D. K.; Platanias, L. C.; Bergan, R. C. Genistein inhibits p38 map kinase activation, matrix metalloproteinase type 2, and cell invasion in human prostate epithelial cells. Cancer Res. 2005, 65, 3470-3478.
79. Thompson, I. M.; Klein, E. A.; Lippman, S. M.; Coltman, C. A.; Djavan, B. Prevention of prostate cancer with finasteride: US/European perspective. Eur. Urol. 2003, 44, 650-655.
80. Moroz, A.; Delella, F. K.; Almeida, R.; Lacorte, L. M.; Favaro, W. J.; Deffune, E.; Felisbino, S. L. Finasteride inhibits human prostate cancer cell invasion through MMP2 and MMP9 downregulation. PLoS One 2013, 8, 12.
81. Toth, M.; Chvyrkova, I.; Bernardo, M. M.; Hernandez-Barrantes, S.; Fridman, R. Pro-MMP-9 activation by the MT1-MMP/MMP-2 axis and MMP-3: Role of TIMP-2 and plasma membranes. Biochem. Biophys. Res. Commun. 2003, 308, 386-395.
82. Varani, J.; Hattori, Y.; Dame, M. K.; Schmidt, T.; Murphy, H. S.; Johnson, K. J.; Wojno, K. J. Matrix metalloproteinases (MMPs) in fresh human prostate tumour tissue and organ-cultured prostate tissue: Levels of collagenolytic and gelatinolytic MMPs are low, variable and different in fresh tissue vs. organ-cultured tissue. Br. J. Cancer 2001, 84, 1076-1083.
83. Scaggiante, B.; Dapas, B.; Bonin, S.; Grassi, M.; Zennaro, C.; Farra, R.; Cristiano, L.; Siracusano, S.; Zanconati, F.; Giansante, C.; et al. Dissecting the expression of EEF1A1/2 genes in human prostate cancer cells: The potential of EEF1A2 as a hallmark for prostate transformation and progression. Br. J. Cancer 2012, 106, 166-173.
84. Aalinkeel, R.; Nair, M. P.; Sufrin, G.; Mahajan, S. D.; Chadha, K. C.; Chawda, R. P.; Schwartz, S. A. Gene expression of angiogenic factors correlates with metastatic potential of prostate cancer cells. Cancer Res. 2004, 64, 5311-5321.
85. Aalinkeel, R.; Nair, B. B.; Reynolds, J. L.; Sykes, D. E.; Mahajan, S. D.; Chadha, K. C.; Schwartz, S. A. Overexpression of MMP-9 contributes to invasiveness of prostate cancer cell line LNCaP. Immunol. Invest. 2011, 40, 447-464.
86. Mañes, S.; Llorente, M.; Lacalle, R. A.; Gómez-Moutón, C.; Kremer, L.; Mira, E.; Marti{dotless}́nez-A, C. The matrix metalloproteinase-9 regulates the insulin-like growth factor-triggered autocrine response in DU-145 carcinoma cells. J. Biol. Chem. 1999, 274, 6935-6945.
87. Nalla, A. K.; Gorantla, B.; Gondi, C. S.; Lakka, S. S.; Rao, J. S. Targeting MMP-9, uPAR, and cathepsin B inhibits invasion, migration and activates apoptosis in prostate cancer cells. Cancer Gene Ther. 2010, 17, 599-613.
88. Gupta, A.; Zhou, C.; Chellaiah, M. Osteopontin and MMP9: Associations with VEGF expression/secretion and angiogenesis in PC3 prostate cancer cells. Cancers 2013, 5, 617-638.
89. Xu, D.; Suenaga, N.; Edelmann, M. J.; Fridman, R.; Muschel, R. J.; Kessler, B. M. Novel MMP-9 substrates in cancer cells revealed by a label-free quantitative proteomics approach. Mol. Cell Proteomics 2008, 7, 2215-2228.
90. Xu, D.; McKee, C. M.; Cao, Y.; Ding, Y.; Kessler, B. M.; Muschel, R. J. Matrix metalloproteinase-9 regulates tumor cell. Invasion through cleavage of protease nexin-1. Cancer Res. 2010, 70, 6988-6998.
91. Dong, Z.; Nemeth, J. A.; Cher, M. L.; Palmer, K. C.; Bright, R. C.; Fridman, R. Differential regulation of matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1 (TIMP-1) and TIMP-2 expression in co-cultures of prostate cancer and stromal cells. Int. J. Cancer 2001, 93, 507-515.
92. Wang, X.; Lee, S. O.; Xia, S.; Jiang, Q.; Luo, J.; Li, L.; Yeh, S.; Chang, C. Endothelial cells enhance prostate cancer metastasis via IL-6→androgen receptor→TGF-beta→MMP-9 signals. Mol. Cancer Ther. 2013, 12, 1026-1037.
93. Smith, P. C.; Lee, S. O.; Xia, S.; Jiang, Q.; Luo, J.; Li, L.; Yeh, S.; Chang, C. Interleukin-6 and prostate cancer progression. Cytok. Growth Fact. Rev. 2001, 12, 33-40.
94. Inoue, K.; Slaton, J. W.; Eve, B. Y.; Kim, S. J.; Perrotte, P.; Balbay, M. D.; Yano, S.; Bar-Eli, M.; Radinsky, R.; Pettaway, C. A.; et al. Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin. Cancer Res. 2000, 6, 2104-2119.
95. Wang, Q.; Slaton, J. W.; Eve, B. Y.; Kim, S. J.; Perrotte, P.; Balbay, M. D.; Yano, S.; Bar-Eli, M.; Radinsky, R.; Pettaway, C. A. Regulation of VEGF, MMP-9 and metastasis by CXCR4 in a prostate cancer cell line. Cell Biol. Int. 2011, 35, 897-904.
96. Sehgal, I.; Thompson, T. C. Neuropeptides induce Mr 92, 000 type IV collagenase (matrix metalloprotease-9) activity in human prostate cancer cell lines. Cancer Res. 1998, 58, 4288-4291.
97. Ishimaru, H.; Kageyama, Y.; Hayashi, T.; Nemoto, T.; Eishi, Y.; Kihara, K. Expression of matrix metalloproteinase-9 and bombesin/gastrin-releasing peptide in human prostate cancers and their lymph node metastases. Acta Oncol. 2002, 41, 289-296.
98. Huang, M.; Narita, S.; Tsuchiya, N.; Ma, Z.; Numakura, K.; Obara, T.; Tsuruta, H.; Saito, M.; Inoue, T.; Horikawa, Y.; et al. Overexpression of Fn14 promotes androgen-independent prostate cancer progression through MMP-9 and correlates with poor treatment outcome. Carcinogenesis 2011, 32, 1589-1596.
99. Johnson, T. R.; Koul, S.; Kumar, B.; Khandrika, L.; Venezia, S.; Maroni, P. D.; Meacham, R. B.; Koul, H. K. Loss of PDEF, a prostate-derived Ets factor is associated with aggressive phenotype of prostate cancer: Regulation of MMP 9 by PDEF. Mol. Cancer 2010, 9, 1476-4598.
100. Schneikert, J.; Peterziel, H.; Defossez, P. A.; Klocker, H.; de Launoit, Y.; Cato, A. C. Androgen receptor-Ets protein interaction is a novel mechanism for steroid hormone-mediated down-modulation of matrix metalloproteinase expression. J. Biol. Chem. 1996, 271, 23907-23913.
101. Miyamoto, H.; Altuwaijri, S.; Cai, Y.; Messing, E. M.; Chang, C. Inhibition of the Akt, cyclooxygenase-2, and matrix metalloproteinase-9 pathways in combination with androgen deprivation therapy: Potential therapeutic approaches for prostate cancer. Mol. Carcinogen. 2005, 44, 1-10.
102. Lateef, A.; Khan, A.; Tahir, M.; Khan, R.; Rehman, M.; Ali, F.; Hamiza, O.; Sultana, S. Androgen deprivation by flutamide modulates uPAR, MMP-9 expressions, lipid profile, and oxidative stress: Amelioration by daidzein. Mol. Cell. Biochem. 2013, 374, 49-59.
103. Lin, T. H.; Lee, S. O.; Niu, Y.; Xu, D.; Liang, L.; Li, L.; Yeh, S. D.; Fujimoto, N.; Yeh, S.; Chang, C. Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide vs. anti-androgen receptor ASC-J9(R) lead to promotion vs. suppression of prostate cancer metastasis. J. Biol. Chem. 2013, 288, 19359-19369.
104. Wilson, C. L.; Matrisian, L. M. Matrilysin: An epithelial matrix metalloproteinase with potentially novel functions. Int. J. Biochem. Cell Biol. 1996, 28, 123-136.
105. Von Bredow, D. C.; Nagle, R. B.; Bowden, G. T.; Cress, A. E. Cleavage of beta 4 integrin by matrilysin. Exp. Cell Res. 1997, 236, 341-345.
106. Powell, W. C.; Fingleton, B.; Wilson, C. L.; Boothby, M.; Matrisian, L. M. The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis. Curr. Biol. 1999, 9, 1441-1447.
107. Noe, V.; Fingleton, B.; Jacobs, K.; Crawford, H. C.; Vermeulen, S.; Steelant, W.; Bruyneel, E.; Matrisian, L. M.; Mareel, M. Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J. Cell Sci. 2001, 114, 111-118.
108. Ito, T. K.; Ishii, G.; Saito, S.; Yano, K.; Hoshino, A.; Suzuki, T.; Ochiai, A. Degradation of soluble VEGF receptor-1 by MMP-7 allows VEGF access to endothelial cells. Blood 2009, 113, 2363-2369.
109. Miyata, Y.; Iwata, T.; Ohba, K.; Kanda, S.; Nishikido, M.; Kanetake, H. Expression of matrix metalloproteinase-7 on cancer cells and tissue endothelial cells in renal cell carcinoma: Prognostic implications and clinical significance for invasion and metastasis. Clin. Cancer Res. 2006, 12, 6998-7003.
110. Jones, L. E.; Humphreys, M. J.; Campbell, F.; Neoptolemos, J. P.; Boyd, M. T. Comprehensive analysis of matrix metalloproteinase and tissue inhibitor expression in pancreatic cancer: Increased expression of matrix metalloproteinase-7 predicts poor survival. Clin. Cancer Res. 2004, 10, 2832-2845.
111. Yamamoto, H.; Iku, S.; Adachi, Y.; Imsumran, A.; Taniguchi, H.; Nosho, K.; Min, Y.; Horiuchi, S.; Yoshida, M.; Itoh, F.; et al. Association of trypsin expression with tumour progression and matrilysin expression in human colorectal cancer. J. Pathol. 2003, 199, 176-184.
112. Kumar-Sinha, C.; Tomlins, S. A.; Chinnaiyan, A. M. Recurrent gene fusions in prostate cancer. Nat. Rev. Cancer 2008, 8, 497-511.
113. Maruta, S.; Sakai, H.; Kanda, S.; Hayashi, T.; Kanetake, H.; Miyata, Y. E1AF expression is associated with extra-prostatic growth and matrix metalloproteinase-7 expression in prostate cancer. APMIS 2009, 117, 791-796.
114. Shin, S.; Oh, S.; An, S.; Janknecht, R. ETS variant 1 regulates matrix metalloproteinase-7 transcription in LNCaP prostate cancer cells. Oncol. Rep. 2013, 29, 306-314.
115. Yu, X.; Wang, Y.; DeGraff, D. J.; Wills, M. L.; Matusik, R. J. Wnt/beta-catenin activation promotes prostate tumor progression in a mouse model. Oncogene 2011, 30, 1868-1879.
116. Zetter, B. R. The cellular basis of site-specific tumor metastasis. N. Engl. J. Med. 1990, 322, 605-612.
117. Jacobs, S. C. Spread of prostatic cancer to bone. Urology 1983, 21, 337-344.
118. Thiolloy, S.; Halpern, J.; Holt, G. E.; Schwartz, H. S.; Mundy, G. R.; Matrisian, L. M.; Lynch, C. C. Osteoclast-derived matrix metalloproteinase-7, but not matrix metalloproteinase-9, contributes to tumor-induced osteolysis. Cancer Res. 2009, 69, 6747-6755.
119. Lynch, C. C.; Hikosaka, A.; Acuff, H. B.; Martin, M. D.; Kawai, N.; Singh, R. K.; Vargo-Gogola, T. C.; Begtrup, J. L.; Peterson, T. E.; Fingleton, B.; et al. MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. Cancer Cell 2005, 7, 485-496.
120. Li, X. Y.; Ota, I.; Yana, I.; Sabeh, F.; Weiss, S. J. Molecular dissection of the structural machinery underlying the tissue-invasive activity of membrane type-1 matrix metalloproteinase. Mol. Biol. Cell 2008, 19, 3221-3233.
121. Sounni, N. E.; Devy, L.; Hajitou, A.; Frankenne, F.; Munaut, C.; Gilles, C.; Deroanne, C.; Thompson, E. W.; Foidart, J. M.; Noel, A. MT1-MMP expression promotes tumor growth and angiogenesis through an up-regulation of vascular endothelial growth factor expression. FASEB J. 2002, 16, 555-564.
122. Chun, T. H.; Sabeh, F.; Ota, I.; Murphy, H.; McDonagh, K. T.; Holmbeck, K.; Birkedal-Hansen, H.; Allen, E. D.; Weiss, S. J. MT1-MMP-dependent neovessel formation within the confines of the three-dimensional extracellular matrix. J. Cell Biol. 2004, 167, 757-767.
123. Nawrocki-Raby, B.; Gilles, C.; Polette, M.; Martinella-Catusse, C.; Bonnet, N.; Puchelle, E.; Foidart, J. M.; van Roy, F.; Birembaut, P. E-Cadherin mediates MMP down-regulation in highly invasive bronchial tumor cells. Am. J. Pathol. 2003, 163, 653-661.
124. Hlubek, F.; Spaderna, S.; Jung, A.; Kirchner, T.; Brabletz, T. Beta-catenin activates a coordinated expression of the proinvasive factors laminin-5 gamma2 chain and MT1-MMP in colorectal carcinomas. Int. J. Cancer 2004, 108, 321-326.
125. Galvez, B. G.; Matias-Roman, S.; Yanez-Mo, M.; Vicente-Manzanares, M.; Sanchez-Madrid, F.; Arroyo, A. G. Caveolae are a novel pathway for membrane-type 1 matrix metalloproteinase traffic in human endothelial cells. Mol. Biol. Cell 2004, 15, 678-687.
126. Jiang, A.; Lehti, K.; Wang, X.; Weiss, S. J.; Keski-Oja, J.; Pei, D. Regulation of membrane-type matrix metalloproteinase 1 activity by dynamin-mediated endocytosis. Proc. Natl. Acad. Sci. USA 2001, 98, 13693-13698.
127. Will, H.; Atkinson, S. J.; Butler, G. S.; Smith, B.; Murphy, G. The soluble catalytic domain of membrane type 1 matrix metalloproteinase cleaves the propeptide of progelatinase A and initiates autoproteolytic activation. Regulation by TIMP-2 and TIMP-3. J. Biol. Chem. 1996, 271, 17119-17123.
128. Sroka, I. C.; McDaniel, K.; Nagle, R. B.; Bowden, G. T. Differential localization of MT1-MMP in human prostate cancer tissue: Role of IGF-1R in MT1-MMP expression. Prostate 2008, 68, 463-476.
129. Tapia, T.; Ottman, R.; Chakrabarti, R. LIM kinase1 modulates function of membrane type matrix metalloproteinase 1: Implication in invasion of prostate cancer cells. Mol. Cancer 2011, 10, 1476-4598.
130. Wang, X.; Wilson, M. J.; Slaton, J. W.; Sinha, A. A.; Ewing, S. L.; Pei, D. Increased aggressiveness of human prostate PC-3 tumor cells expressing cell surface localized membrane type-1 matrix metalloproteinase (MT1-MMP). J. Androl. 2009, 30, 259-274.
131. Nagakawa, O.; Murakami, K.; Yamaura, T.; Fujiuchi, Y.; Murata, J.; Fuse, H.; Saiki, I. Expression of membrane-type 1 matrix metalloproteinase (MT1-MMP) on prostate cancer cell lines. Cancer Lett. 2000, 155, 173-179.
132. Jennbacken, K.; Gustavsson, H.; Welen, K.; Vallbo, C.; Damber, J. E. Prostate cancer progression into androgen independency is associated with alterations in cell adhesion and invasivity. Prostate 2006, 66, 1631-1640.
133. Bair, E. L.; Chen, M. L.; McDaniel, K.; Sekiguchi, K.; Cress, A. E.; Nagle, R. B.; Bowden, G. T. Membrane type 1 matrix metalloprotease cleaves laminin-10 and promotes prostate cancer cell migration. Neoplasia 2005, 7, 380-389.
134. Nguyen, H. L.; Zucker, S.; Zarrabi, K.; Kadam, P.; Schmidt, C.; Cao, J. Oxidative stress and prostate cancer progression are elicited by membrane-type 1 matrix metalloproteinase. Mol. Cancer Res. 2011, 9, 1305-1318.
135. Bonfil, R. D.; Dong, Z.; Trindade Filho, J. C.; Sabbota, A.; Osenkowski, P.; Nabha, S.; Yamamoto, H.; Chinni, S. R.; Zhao, H.; Mobashery, S.; et al. Prostate cancer-associated membrane type 1-matrix metalloproteinase: A pivotal role in bone response and intraosseous tumor growth. Am. J. Pathol. 2007, 170, 2100-2111.
136. Sabbota, A. L.; Kim, H. R.; Zhe, X.; Fridman, R.; Bonfil, R. D.; Cher, M. L. Shedding of RANKL by tumor-associated MT1-MMP activates Src-dependent prostate cancer cell migration. Cancer Res. 2010, 70, 5558-5566.
137. Kawamata, H.; Kawai, K.; Kameyama, S.; Johnson, M. D.; Stetler-Stevenson, W. G.; Oyasu, R. Over-expression of tissue inhibitor of matrix metalloproteinases (TIMP1 and TIMP2) suppresses extravasation of pulmonary metastasis of a rat bladder carcinoma. Int. J. Cancer 1995, 63, 680-687.
138. Chen, Y.; Wei, X.; Guo, C.; Jin, H.; Han, Z.; Han, Y.; Qiao, T.; Wu, K.; Fan, D. Runx3 suppresses gastric cancer metastasis through inactivation of MMP9 by upregulation of TIMP-1. Int. J. Cancer 2011, 129, 1586-1598.
139. Deng, X.; He, G.; Levine, A.; Cao, Y.; Mullins, C. Adenovirus-mediated expression of TIMP-1 and TIMP-2 in bone inhibits osteolytic degradation by human prostate cancer. Int. J. Cancer 2008, 122, 209-218.
140. Stetler-Stevenson, W. G.; Krutzsch, H. C.; Liotta, L. A. Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family. J. Biol. Chem. 1989, 264, 17374-17378.
141. Lee, S. J.; Yoo, H. J.; Bae, Y. S.; Kim, H. J.; Lee, S. T. TIMP-1 inhibits apoptosis in breast carcinoma cells via a pathway involving pertussis toxin-sensitive G protein and c-Src. Biochem. Biophys. Res. Commun. 2003, 312, 1196-1201.
142. Boulday, G.; Fitau, J.; Coupel, S.; Soulillou, J. P.; Charreau, B. Exogenous tissue inhibitor of metalloproteinase-1 promotes endothelial cell survival through activation of the phosphatidylinositol 3-kinase/Akt pathway. Ann. NY Acad. Sci. 2004, 1030, 28-36.
143. Guedez, L.; Martinez, A.; Zhao, S.; Vivero, A.; Pittaluga, S.; Stetler-Stevenson, M.; Raffeld, M.; Stetler-Stevenson, W. G. Tissue inhibitor of metalloproteinase 1 (TIMP-1) promotes plasmablastic differentiation of a Burkitt lymphoma cell line: Implications in the pathogenesis of plasmacytic/plasmablastic tumors. Blood 2005, 105, 1660-1668.
144. Hayakawa, T.; Yamashita, K.; Tanzawa, K.; Uchijima, E.; Iwata, K. Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells A possible new growth factor in serum. FEBS Lett. 1992, 298, 29-32.
145. Bigelow, R.; Williams, B.; Carroll, J.; Daves, L.; Cardelli, J. TIMP-1 overexpression promotes tumorigenesis of MDA-MB-231 breast cancer cells and alters expression of a subset of cancer promoting genes in vivo distinct from those observed in vitro. Breast Cancer Res. Treat. 2009, 117, 31-44.
146. Xia, Y.; Yeddula, N.; Leblanc, M.; Ke, E.; Zhang, Y.; Oldfield, E.; Shaw, R. J.; Verma, I. M. Reduced cell proliferation by IKK2 depletion in a mouse lung-cancer model. Nat. Cell Biol. 2012, 14, 257-265.
147. Zeng, Z. S.; Cohen, A. M.; Zhang, Z. F.; Stetler-Stevenson, W.; Guillem, J. G. Elevated tissue inhibitor of metalloproteinase 1 RNA in colorectal cancer stroma correlates with lymph node and distant metastases. Clin. Cancer Res. Cancer Res. 1995, 1, 899-906.
148. Nakopoulou, L.; Giannopoulou, I.; Stefanaki, K.; Panayotopoulou, E.; Tsirmpa, I.; Alexandrou, P.; Mavrommatis, J.; Katsarou, S.; Davaris, P. Enhanced mRNA expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in breast carcinomas is correlated with adverse prognosis. J. Pathol. 2002, 197, 307-313.
149. Aldulaymi, B.; Bystrom, P.; Berglund, A.; Christensen, I. J.; Brunner, N.; Nielsen, H. J.; Glimelius, B. High. plasma TIMP-1 and serum CEA levels during combination chemotherapy for metastatic colorectal cancer are significantly associated with poor outcome. Oncology 2010, 79, 144-149.
150. Crocker, M.; Ashley, S.; Giddings, I.; Petrik, V.; Hardcastle, A.; Aherne, W.; Pearson, A.; Bell, B. A.; Zacharoulis, S.; Papadopoulos, M. C. Serum angiogenic profile of patients with glioblastoma identifies distinct tumor subtypes and shows that TIMP-1 is a prognostic factor. Neuro-oncology 2011, 13, 99-108.
151. Guedez, L. and W. G. Stetler-Stevenson, The prognostic value of TIMP-1 in multiple myeloma. Leuk. Res. 2010, 34, 576-577.
152. Yoshikawa, T.; Cho, H.; Tsuburaya, A.; Kobayashi, O. Impact of plasma tissue inhibitor of metalloproteinase-1 on long-term survival in patients with gastric cancer. Gastric Cancer 2009, 12, 31-36.
153. Yoshino, Y.; Kageshita, T.; Nakajima, M.; Funakubo, M.; Ihn, H. Clinical relevance of serum levels of matrix metallopeptidase-2, and tissue inhibitor of metalloproteinase-1 and-2 in patients with malignant melanoma. J. Dermatol. 2008, 35, 206-214.
154. Yukawa, N.; Yoshikawa, T.; Akaike, M.; Sugimasa, Y.; Rino, Y.; Masuda, M.; Imada, T. Impact of plasma tissue inhibitor of matrix metalloproteinase-1 on long-term survival in patients with colorectal cancer. Oncology 2007, 72, 205-208.
155. Gong, Y.; Scott, E.; Lu, R.; Xu, Y.; Oh, W. K.; Yu, Q. TIMP-1 promotes accumulation of cancer associated fibroblasts and cancer progression. PLoS One 2013, 8.
156. Ross, R. W.; Galsky, M. D.; Scher, H. I.; Magidson, J.; Wassmann, K.; Lee, G. S.; Katz, L.; Subudhi, S. K.; Anand, A.; Fleisher, M.; et al. A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: A prospective study. Lancet Oncol. 2012, 13, 1105-1113.
157. Gilbert, L. A.; Hemann, M. T. DNA damage-mediated induction of a chemoresistant niche. Cell 2010, 143, 355-366.
158. Nemunaitis, J.; Poole, C.; Primrose, J.; Rosemurgy, A.; Malfetano, J.; Brown, P.; Berrington, A.; Cornish, A.; Lynch, K.; Rasmussen, H.; et al. Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: Selection of a biologically active and tolerable dose for longer-term studies. Clin. Cancer Res. 1998, 4, 1101-1109.
159. Knox, J. D.; Bretton, L.; Lynch, T.; Bowden, G. T.; Nagle, R. B. Synthetic matrix metalloproteinase inhibitor, BB-94, inhibits the invasion of neoplastic human prostate cells in a mouse model. Prostate 1998, 35, 248-254.
160. Lein, M.; Jung, K.; Le, D. K.; Hasan, T.; Ortel, B.; Borchert, D.; Winkelmann, B.; Schnorr, D.; Loenings, S. A. Synthetic inhibitor of matrix metalloproteinases (batimastat) reduces prostate cancer growth in an orthotopic rat model. Prostate 2000, 43, 77-82.
161. Coussens, L. M.; Tinkle, C. L.; Hanahan, D.; Werb, Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 2000, 103, 481-90.
162. McCawley, L. J.; Crawford, H. C.; King, L. E., Jr.; Mudgett, J.; Matrisian, L. M. A protective role for matrix metalloproteinase-3 in squamous cell carcinoma. Cancer Res. 2004, 64, 6965-6972.
163. Balbin, M.; Fueyo, A.; Tester, A. M.; Pendas, A. M.; Pitiot, A. S.; Astudillo, A.; Overall, C. M.; Shapiro, S. D.; Lopez-Otin, C. Loss of collagenase-2 confers increased skin tumor susceptibility to male mice. Nat. Genet. 2003, 35, 252-257.
164. Houghton, A. M.; Grisolano, J. L.; Baumann, M. L.; Kobayashi, D. K.; Hautamaki, R. D.; Nehring, L. C.; Cornelius, L. A.; Shapiro, S. D. Macrophage elastase (matrix metalloproteinase-12) suppresses growth of lung metastases. Cancer Res. 2006, 66, 6149-6155.